CURRICULUM VITAE
Elizabeth E. Hopp MD
Elizabeth E. Hopp MD
Assistant Professor
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Division of Gynecologic Oncology
OFFICE ADDRESS: |
Froedtert/MCW Laboratory Building |
9200 W Wisconsin Ave |
Milwaukee, WI 53226 |
EDUCATION: |
08/2008 - 05/2012 Doctor of Medicine with Honors in Research, Medical College of Wisconsin, Milwaukee, WI |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
06/2012 - 06/2016 Resident, Obstetrics and Gynecology, Medical College of Wisconsin Affiliated Hospitals, Milwaukee, WI |
07/2016 - 06/2019 Fellow, Obstetrics and Gynecology, Gynecologic Oncology, University Hospitals Cleveland Medical Center, Cleveland, OH |
FACULTY APPOINTMENTS: |
07/2016 - 06/2019 Clinical Instructor, Reproductive Biology, Case Western Reserve University, Cleveland, OH |
08/2019 - Present Assistant Professor, Obstetrics and Gynecology, Gynecologic Oncology, Medical College of Wisconsin, Milwaukee, WI |
ADMINISTRATIVE APPOINTMENTS: |
08/2024 - Present 4PV Medical Director, Froedtert & the Medical College of Wisconsin |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
06/2020 - Present Course Director of Gynecologic Oncology Acting Internship, Obstetrics and Gynecology, Gynecologic Oncology, Medical College of Wisconsin, Milwaukee, WI |
HOSPITAL STAFF PRIVILEGES: |
08/2019 - Present Froedtert and Medical College of Wisconsin, 9200 W Wisconsin Ave, Milwaukee, WI 53226 |
08/2019 - Present Community Memorial Hospital, W180N8085 Town Hall Rd, Menomonee Falls, WI 53051 |
08/2019 - Present St. Joseph's Hospital, 3200 Pleasant Valley Rd, West Bend, WI, 53095 |
12/2019 - Present Children's Hospital of Wisconsin, 8915 W Connell Ct, Milwaukee, WI 53226 |
SPECIALTY BOARDS AND CERTIFICATION: |
Board Certified | Issue Date | Expiration |
Obstetrics and Gynecology Certification | 01/2019 | 12/2024 |
Gynecologic Oncology Subspecialty Certification | 04/2022 | 12/2024 |
Licensure | Number | Issue Date | Expiration |
Wisconsin License | 61414-20 | 10/10/2013 | 10/31/2025 |
Ohio License | 35.128780 | 05/23/2016 | 10/01/2026 |
AWARDS AND HONORS: |
2012 Dr. John J. and Joan M. Brennan Award for Excellence in Obstetrics and Gynecology , Medical College of Wisconsin |
2012 Honors in Research , Medical College of Wisconsin |
2014 Dr. George W. Morley Memorial Paper Award , Central Association of Obstetricians and Gynecologists |
2016 MCWAH Research Award , Medical College of Wisconsin Affiliated Hospitals |
2019 Scholarship in Teaching Award , Case Western Reserve University School of Medicine |
2021 Editor's Choice featured article in July issue of Gynecologic Oncology |
2021 MCW's Outstanding Medical Student Teachers for 2020-2021, Medical College of Wisconsin |
2023 100 Women of Distinction 1923-2023, Our Lady of the Elms School |
2024 Swiftest Accrual to a Clinical Trial, Ovarian Subcommittee NRG Oncology |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
2015 - Present Society of Gynecologic Oncology |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
01/2020 - Present General Member, Uterine Corpus Subcommittee, NRG Oncology |
01/2020 - Present New Investigators Committee, NRG Oncology |
11/2023 - Present Core Member, Rare Tumor Committee, NRG Oncology |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
INVITED LECTURES/WORKSHOPS/PRESENTATIONS: |
Regional |
Hopp E, From Bedside to Clinical Trial: Research Innovation in Adult-type granulosa cell tumors of the ovary, University Hospitals OB/GYN Research and Innovation Day, Cleveland, OH, 04/24/2024 |
Local |
Hopp E, Klatt TE, Effect of a Best-Practice Alert on the Rate of Influenza Vaccination of Pregnant Women, Pathways Research Oral Presentation at at Medical College of Wisconsin, Milwaukee, WI, 09/2009 |
Hopp E, Fertility after Bariatric Surgery, Department of Obstetrics and Gynecology Grand Rounds, Milwaukee, WI, 05/2013 |
Hopp E, Fetal Brain Abnormalities, St. Joseph's Hospital Grand Rounds, Milwaukee, WI, 01/2014 |
Hopp E, Fertility Preservation in Gynecologic Cancer, Department of Obstetrics and Gynecology Grand Rounds, Milwaukee, WI, 04/2014 |
Hopp E, Osborne J, Schneider D, Bojar C, Uyar D, A Prospective Study on the Incidence of Post-Operative Lymphedema in Women with Endometrial Cancer, Medical College of Wisconsin Obstetrics & Gynecology Research Day, Milwaukee, WI, 06/2014 |
Hopp E, Zanotti KM, Smoking Cessation for Women with Gynecologic Cancers, Video presentation, Cleveland, OH, 12/2017 |
Hopp E, Joseph P, Nakayama J, Zanotti KM, Nagel CI, Waggoner SW, DiFeo A, Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer, Oral Presentation for Thesis Defense to Division of Gynecologic Oncology
Oral Presentation for Thesis Defense to Division of Gynecologic Oncology
Oral Presentation for Thesis Defense to Division of Gynecologic Oncology
Oral Presentation for Thesis Defense to Division of Gynecologic Oncology, Cleveland, OH, 05/2019 |
Hopp E, Familial Cancer Syndromes in Gynecologic Oncology: Screening and Management, Medical College of Wisconsin Department of Obstetrics and Gynecology Grand Rounds, Milwaukee, WI, 01/2020 |
Hopp E, Ovarian Cancer, Hematology/Oncology Fellowship Didactics, Medical College of Wisconsin, 11/24/2021 |
Hopp E, Cervical Dysplasia and Cervical Cancer Management in Pregnancy, Department of Obstetrics and Gynecology Grand
Rounds, Medical College of Wisconsin; Milwaukee, WI, 11/08/2023 |
Hopp E, Ovarian Cancer, Hematology/Oncology Fellowship Didactics, Medical College of Wisconsin, 01/15/2024 |
PEER REVIEWED WORKSHOPS/PRESENTATIONS: |
International |
J-M. Lee, A. Miller, P. Rose, M. AlHilli, C. Washington, V. John, C. Shah, K. Matsuo, J. Siedel, D.S. Miller,
J. Chan, E. Hopp, E.C. Kohn, K.N. Moore, J.F. Liu, Randomized phase II trial of durvalumab
in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or
durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian
cancer with prior bevacizumab (NRG-GY023), ESMO Congress 2023, Madrid, Spain, 10/20/2023 - 10/24/2023 |
Mayadev J, Deng W, Zamarin D, Lankes H, Kim H, Chino J, Banberry B, Sherry N, Ghamande S, Ferguson
C, Mell L, Hollman L, Matthews C, O'Malley D, Olawaiye A, Hopp E, O’Cearbhaill R, Aghajanian C,
Schilder R, Radiation quality and workflow in NRG GY017: anti PD-L1 (atezolizumab)
as an immune primer or concurrently with RT for node positive locally advanced cervical cancer, IGCS 2023 Annual Global Meeting, Seoul, Republic of Korea, 11/05/2023 - 11/07/2023 |
Barlin JN, Lim PC, Thomes Pepin J, Hopp EE, Cloven NG, Lee C, Eshed HD, Black D, Cottrill HM, Hand L, O’Malley DM, Chuang LT, Willmott L, Chisamore M, Shpyro S, Durbin J, Zheng P, Liu Y, Monk BJ, A Phase 2 randomized dose optimization trial of gotistobart, a pH-sensitive anti-CTLA-4, in combination with pembrolizumab in platinum-resistant ovarian cancer (PROC, PRESERVE-004/GOG-3081; NCT05446298); Accepted for oral presentation, ESMO, Barcelona, Spain, 09/13/2024 - 09/17/2024 |
National |
Hopp E, Bishop E, Cossette S, Ramchandran R., Sucrose nonfermenting 1-related kinase (SNRK) expression in ovarian cancer and correlation with clinical features., American Association for Cancer Research Annual Meeting, New Orleans, LA, 04/16/2016 - 04/20/2016 |
Hopp E, Joseph P, Nakayama J, Zanotti KM, Nagel CI, Waggoner SW, DiFeo A, Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer, Society of Gynecologic Oncology Annual Meeting, New Orleans, LA, 03/24/2018 - 03/27/2018 |
Hopp E, Somasegar S, Webb Hooper M, Zanotti KM, Improving value-based care in cervical cancer through incorporation of consistent value-based teaching in a gynecologic oncology fellowship, Society of Gynecologic Oncology Annual Meeting, New Orleans, LA, 03/24/2018 - 03/27/2018 |
Bhide S, Collada A, Reid A, Jackson C, Hopp E, Nakayama J., The Ovarian Cancer Message Isn’t Getting Out: Using Google Search Data to Gauge Ovarian Cancer Awareness, Society of Gynecologic Oncology Annual Meeting, Honolulu, Hawaii, 03/16/2019 - 03/19/2019 |
Bishop EA, Hopp EE, Kaljo K, Rader J, Advancing diversity of the current cancer research workforce through novel virtual teaching methods during the COVID-19 pandemic, Society of Gynecologic Oncology Annual Meeting on Women's Cancer, Virtual, 03/2021 |
McAlarnen LA, Monroe A, Bishop EA, Hopp EE, Rader JS, Bradley WH, Streitenberger K, Uyar D, Same day discharge after robotic hysterectomy for gynecologic malignancy: a study of cost analysis and resource utilization, Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Virtual, 03/2021 |
Bradley WH, Hopp EE, Rader JS, Bishop EA, Prasad Hayes M, Taylor NP, Uyar D, An open label, non-randomized multisite phase II trial combining bevacizumab,
atezolizumab, and rucaparib for the treatment of previously treated recurrent and
progressive endometrial carcinoma: The EndoBARR Trial: NCT03694262, Society Of Gynecologic Oncology Annual Meeting on Women's Cancer, Virtual, 03/2021 |
McAlarnen LA, Sona M, Tischer K, Small C, Bedi M, Erickson B, Hopp EE, Exploring social vulnerability in locally advanced cervical cancer patients undergoing brachytherapy irradiation, 14th American Association for Cancer Research Conference: The Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, Virtual, 10/2021 |
McAlarnen LA, Small C, Tischer K, Sona M, Bedi M, Erickson B, Hopp EE, Does social vulnerability impact cervical cancer patients undergoing definitive irradiation including brachytherapy? A single institution’s experience, Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Phoenix, AZ, 03/2022 |
Summey RM, Hopp EE, Moh M, Bishop EA, Uyar DA, Bradley WH, Rader JS, A Case Series of Androgen Receptor (AR) Inhibition by Bicalutamide in combination with Leuprolide Acetate and Exemestane in Recurrent AR Positive Adult-Type Ovarian Granulosa Cell Tumor (AGCT), Society of Gynecologic Oncology Annual Meeting on Women’s Cancer, Phoenix, AZ, 03/2022 |
Bradley WH, Prasad Hayes M, Taylor N, Rader JS, Bishop E, Hopp EE, McAlarnen L, Liegl M, Simpson P, Uyar D, An Open Label, Non-randomized, Multisite Phase II Trial Combining Bevacizumab, Atezolizumab, and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Cancer, ASCO, Chicago, IL, 06/2022 |
Summey RM, Parashar D, Iden M, Schmidt R, Rader JS, Hopp E, Exploration and exploitation of hormonal pathways in adult granulosa cell tumors to develop targeted therapeutics., Society of Gynecologic Oncology Annual Meeting, Tampa, FL, 03/2023 |
Depke MG, Summey RM, Hopp E, Cardiovascular disease contributes to racial disparities in endometrial cancer outcomes, American Society of Clinical Oncology, Chicago, IL, 06/2023 |
Sequeira N, Summey R, Depke M, Aliani R, Gecsi K, Krueper A, Hopp E, Bradley W, Mental Health in Gynecologic Oncologists: Unmet Needs, Barriers to Care, and Possibilities for Improvement, Society of Gynecologic Oncology Winter Meeting, Olympic Valley, CA, 01/25/2024 - 01/27/2024 |
Regional |
Hopp E, Klatt TE, Powell M, Eastwood D, Szabo A, Effect of Restrictive Episiotomy on Long-Term Maternal Perineal Healing, Central Association of Obstetricians and Gynecologists Annual Meeting, Napa, CA, 10/16/2013 - 10/19/2013 |
Hopp E, Osborne J, Schneider D, Bojar C, Uyar D, A Prospective Study on the Incidence of Post-Operative Lymphedema in Women with Endometrial Cancer., Central Association of Obstetricians and Gynecologists Annual Meeting, Albuquerque, NM, 10/08/2014 - 10/11/2014 |
Hopp E, Cossette SM, Kumar SN, Eastwood D, Ramchandran R, Bishop E, Sucrose non-fermenting related kinase expression in ovarian cancer and correlation with clinical features, Cleveland Society of OB/GYN Research Day, Cleveland, OH, 05/17/2017 |
Hopp E, Joseph P, Nakayama J, Zanotti KM, Nagel CI, Waggoner SW, DiFeo A, Identifying susceptibilities and pharmacodynamic biomarkers for mirvetuximab soravtansine in high-grade ovarian and endometrial cancer, Cleveland Society of OB/GYN Research Day, Cleveland, OH, 05/16/2018 |
Hopp E, Webb Hooper M, Somasegar S, Zanotti K, Improving value-based care in cervical cancer through incorporation of consistent value-based teaching in a gynecologic oncology fellowship, Cleveland Society of OB/GYN Research Day, Cleveland, OH, 05/15/2019 |
McAlarnen LA, Tsaih S, Aliani R, Simske NM, Hopp EE, Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum, Heartland Association of Gynecologic Oncology Annual Meeting, Madison, WI, 09/17/2021 |
Sequeira N, Summey R, Depke M, Aliani R, Gecsi K, Krueper A, Hopp E, Bradley W, Mental Health in Gynecologic Oncologists: Unmet Needs, Barriers to Care, and Possibilities for Improvement, Heartland Association of Gynecologic Oncology Annual Meeting, Minneapolis, MN, 09/22/2023 - 09/23/2023 |
Sequeira N, Summey R, Depke M, Aliani R, Gecsi K, Krueper A, Hopp E, Bradley W, Mental Health in Gynecologic Oncologists: Unmet Needs, Barriers to Care, and Possibilities for Improvement, ACOG District VI Meeting, Omaha, NE, 09/30/2023 - 10/01/2023 |
Local |
Hopp E, Schlotthauer A, Hargarten S., Evaluation of Kohl’s Cares for Kids Safety Campaign, Medical College of Wisconsin Summer Research Program Poster Session, Milwaukee, WI, 09/2008 |
Hopp E, Klatt TE, Effect of a Best-Practice Alert on the Rate of Influenza Vaccination of Pregnant Women, Medical College of Wisconsin Summer Research Program Poster Session, Milwaukee, WI, 09/2009 |
Hopp E, Vulvar Dystrophies, Department of Obstetrics and Gynecology Grand Rounds, Milwaukee, WI, 01/2015 |
McAlarnen LA, Aliani R, Simske N, Hopp EE, Investigating social vulnerability among patients participating in gynecologic oncology virtual visits during the COVID-19 pandemic, Medical College of Wisconsin Research Week, Milwaukee, WI, 02/24/2021 |
Duyar-Ayerdi S, Depke M, Young C, O’Connell M, Hopp E, Diagnosis, Management, and Outcomes in Serous Endometrial Intraepthelial Carcinoma, MCW Cancer Center Trainee Symposium, Milwaukee, WI, 03/07/2024 |
COMMITTEE SERVICE: |
Medical College of Wisconsin |
06/2020 - Present Member, Gynecology Quality Committee, Medical College of Wisconsin Department of Obstetrics and Gynecology |
08/2020 - Present Member, Resident Research Committee, Medical College of Wisconsin Department of Obstetrics and Gynecology |
09/2020 - 01/2021 Member, Curriculum Exploration Project-Principle 3 |
08/2021 - 08/2023 OB/GYN Elected Representative, Faculty Council |
11/2023 - Present Member, IIT Steering Committee, Medical College of Wisconsin Cancer Center |
01/2024 - 03/2024 Cancer Center Trainee Symposium Judge and abstract reviewer, Medical College of Wisconsin |
06/2024 - Present Member, Academic Incentive Committee, Department of Obstetrics and Gynecology, Medical College of Wisconsin |
Hospital |
2016 - 2019 Departmental Research Review Committee, Obstetrics and Gynecology, University Hospitals Cleveland Medical Center |
MCW TEACHING ACTIVITIES: |
Medical Student Education |
2013 Instructor for Medical Student Pelvic Exam Course |
2015 Instructor for Medical Student Pelvic Exam Course |
01/2020 - Present M1, M2 Clinical Apprenticeship Course |
03/03/2020 M2 Foundational Capstone-Pelvic Exams |
04/09/2020 Medical Student Lecture: Cervical and Vulvar Cancer |
02/21/2023 M2 Foundational Capstone Pelvic Exams |
Resident and Fellow Education |
2019 - Present Morbidity and Mortality Conference Moderator |
01/08/2020 Gynecologic Oncology CREOG Review |
04/09/2020 Resident Lecture: Management of Early Stage Cervical Cancer |
05/05/2020 Resident Lecture: Ovarian Germ Cell Tumors |
05/13/2020 Resident Lecture: Pelvic Anatomy for OB/GYN's |
05/28/2020 Interactive Brachytherapy Course |
09/30/2020 Chemotherapy |
05/26/2021 Management of Chemotherapy Toxicity |
10/06/2021 Uterine Sarcoma |
01/26/2022 Recurrent and Metastatic Cervical Cancer |
07/06/2022 Gestational Trophoblastic Disease |
07/13/2022 Early Stage Endometrial Cancer |
09/14/2022 Management of Cervical Dysplasia and Cervical Cancer in Pregnancy |
10/12/2022 Early Stage Cervical Cancer |
07/12/2023 Resident Education: Cervical Cancer |
08/02/2023 Early Endometrial Cancer |
10/25/2023 Uterine Carcinoma and Carcinosarcoma |
05/22/2024 Gestational Trophoblastic Disease |
Community/Lay Public |
02/25/2020 Community Educational Lecture: Family History in Cancer Screening and Treatment |
11/09/2020 Community Educational Lecture: Family History in Cancer Screening and Treatment |
2020 - 2023 SPARCC program-Department of OB/GYN |
11/02/2021 Community Educational Lecture: Ovarian Cancer Awareness |
01/08/2022 Latest Word on Medicine Cervical Cancer |
09/14/2022 Latest Word on Medicine Ovarian Cancer Awareness Month |
01/05/2024 Latest Word on Medicine Cervical Cancer Awareness Month |
EXTRAMURAL TEACHING: |
Community/Lay Public |
2016 University Hospitals Cleveland Medical Center, Gynecologic Oncology Community Outreach Presentation |
PROGRAMMATIC DEVELOPMENTS: |
Educational Programs |
Student |
2020 - 2023 SPARCC program (Student-Centered Pipeline to Advance Research in Cancer Centers) |
Clinical Programs |
2016 - 2019 Development of Smoking Cessation Program for Gynecologic Oncology patients |
Community Programs |
MCW Gyn Onc Instagram Creator |
COMMUNITY SERVICE ACTIVITIES: |
2013 - 2014 ACOG Junior Fellow Section Vice Chair-Wisconsin |
2014 - 2015 ACOG Chair of District VI Task Force for Programs/Contests |
2014 - 2015 ACOG Junior Fellow Section Chair-Wisconsin |
11/07/2019 Career Day at New Berlin Eisenhower Middle/High School |
06/2021 - Present Ray of Hope Run-Supporting Ovarian Cancer Research |
2023 - Present St. Dominic Catholic School Knights Move Fundraising Committee |
CLINICAL TRIALS: |
01/22/2024 - Present National PI of NRG-GY033: A PHASE II STUDY OF ANDROGEN RECEPTOR (AR) INHIBITION BY DAROLUTAMIDE IN COMBINATION WITH LEUPROLIDE ACETATE AND EXEMESTANE IN RECURRENT ADULT-TYPE OVARIAN GRANULOSA CELL TUMOR |
Currently site PI on 5 FDA regulated studies and Sub-Investigator on over 10 clinical trials |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Ma R, Hopp EA, Decker NM, Loucks A, Johnson JR, Moskal J, Basu M, Banerjee S, Basu S. Regulation of glycosyltransferase genes in apoptotic breast cancer cells induced by L: -PPMP and cisplatin. Adv Exp Med Biol. 2011;705:621-42. |
2. Klatt TE, Hopp E. Effect of a best-practice alert on the rate of influenza vaccination of pregnant women. Obstet Gynecol. 2012 Feb;119(2 Pt 1):301-5. |
3. Palatnik A, Hopp EE, Hoogerland D. Small bowel obstruction after vaginal hysterectomy with bilateral salpingo-oophorectomy Journal of Gynecologic Surgery. 1 October 2012;28(5):372-374. |
4. Hopp EE, Osborne JL, Schneider DK, Bojar CJ, Uyar DS. A prospective pilot study on the incidence of post-operative lymphedema in women with endometrial cancer. Gynecol Oncol Rep. 2016 Jan;15:25-8. PMCID: PMC4750017 |
5. Liu P, Iden M, Fye S, Huang YW, Hopp E, Chu C, Lu Y, Rader JS. Targeted, Deep Sequencing Reveals Full Methylation Profiles of Multiple HPV Types and Potential Biomarkers for Cervical Cancer Progression. Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):642-650. |
6. Hopp EE, Cossette SM, Kumar SN, Eastwood D, Ramchandran R, Bishop E. Sucrose Non-Fermenting Related Kinase Expression in Ovarian Cancer and Correlation with Clinical Features. Cancer Invest. 2017 Aug 09;35(7):456-462. PMCID: PMC6167932 |
7. Kristine Zanotti, Sahana Somasegar, Monica Webb Hooper and Elizabeth Hopp. Improving Value-Based Care Education in a Fellowship by Incorporating ACGME Competencies Journal of Graduate Medical Education. Kristine Zanotti, Sahana Somasegar, Monica Webb Hooper, and Elizabeth Hopp. Improving Value-Based Care Education in a Fellowship by Incorporating ACGME Competencies. Journal of Gra. |
8. McAlarnen LA, Tsaih SW, Aliani R, Simske NM, Hopp EE. Virtual visits among gynecologic oncology patients during the COVID-19 pandemic are accessible across the social vulnerability spectrum. Gynecol Oncol. 2021 Jul;162(1):4-11. PMCID: PMC8111476 |
9. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Rader JS, Pradeep S, Chaluvally-Raghavan P. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance Cancers. February-2 2022;14(4). |
10. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Correction to: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance (Cancers, (2022), 14, 958) Cancers. May-2 2022;14(10). |
11. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. Cancers (Basel). 2022 Feb 15;14(4). PMCID: PMC8870411 |
12. Summey RM, Rader JS, Moh M, Bradley W, Uyar D, Bishop E, McAlarnen L, Hopp E. A case series of triplet anti-hormonal therapy in androgen receptor-positive recurrent adult ovarian granulosa cell tumor Gynecologic Oncology Reports. December 2022;44. |
13. Parashar D, Geethadevi A, Mittal S, McAlarnen LA, George J, Kadamberi IP, Gupta P, Uyar DS, Hopp EE, Drendel H, Bishop EA, Bradley WH, Bone KM, Rader JS, Pradeep S, Chaluvally-Raghavan P. Correction: Parashar et al. Patient-Derived Ovarian Cancer Spheroids Rely on PI3K-AKT Signaling Addiction for Cancer Stemness and Chemoresistance. <i>Cancers</i> 2022, <i>14</i>, 958. Cancers (Basel). 2022 May 16;14(10). PMCID: PMC9140135 |
14. McAlarnen LA, Maurer JE, Knaub A, Hopp E, Streitenberger K, Bishop E, Bradley W, Rader J, Uyar D. Same-Day Discharge After Robotic Hysterectomy: A Resource Utilization and Quality Improvement Project. WMJ. 2022 Oct;121(3):243-246. |
15. Uyar D, Michener CM, Bishop E, Hopp E, Simpson P, Zhang L, Rader JS, Rose PG, Mahdi HS, Debernardo R, Christian Q, Bradley W. Carboplatin, paclitaxel, and pembrolizumab followed by pembrolizumab maintenance for primary treatment of incompletely resected epithelial ovarian cancer Frontiers in Oncology. 2024;14. |
16. Summey RM, Gornstein E, Decker B, Dougherty KC, Rader JS, Hopp E. Landscape of potential germline pathogenic variants in select cancer susceptibility genes in patients with adult-type ovarian granulosa cell tumors. Cancer Med. 2024 Jun;13(12):e7340. PMCID: PMC11187164 |
17. Summey RM, Iden M, Tsaih S-M, Schmidt R, Parashar D, Wang S, Rader JS, Hopp E. Combination hormonal drug therapy inhibits in vitro growth of adult ovarian granulosa tumor cells. Submitted to Heliyon and undergoing revisions. |
18. Moh M, Puzyrenko A, Summey R, Rader JS, Herrera Cano GE, Gavina JV, Rui H, Sun Y, Hopp E. Clinicopathologic Characteristics of a Single-institution Cohort of Ovarian Adult Granulosa Cell Tumors, With Biomarker and Therapeutic Implications Utilizing the Detection of Androgen, Estrogen, and Progesterone Hormone Receptor Expression by Immunohistochemistry. Int J Gynecol Pathol. 2024 Sep 01;43(5):527-534. |
Non-Refereed Journal Publications/Original Papers |
1. Hopp E, Klatt TE. A Comparison of Maternal Outcomes after Anterior and Posterior Lacerations Associated with Childbirth. Honors Thesis. May 2012. |
Abstracts |
1. Hopp E, Martin LTJ, Kumar J, Nakayama J. Incidence of venous thromboembolism in the gynecologic cancer patient population at a single institution after implementation of pre-operative venous thromboembolism prophylaxis. Online abstract publication at 2018 ASCO Annual Meeting. |
2. J-M. Lee, A. Miller, P. Rose, M. AlHilli, C. Washington, V. John, C. Shah, K. Matsuo, J. Siedel, D.S. Miller, J. Chan, E. Hopp, E.C. Kohn, K.N. Moore, J.F. Liu. 746MO Randomized phase II trial of durvalumab in combination with olaparib and cediranib (DOC) compared to olaparib and cediranib (OC) or durvalumab and cediranib (DC) or standard of care chemotherapy (SOC) in platinum-resistant ovarian cancer with prior bevacizumab (NRG-GY023). Annals of Oncology 2023;34(2):S511.
|
3. Mayadev J, Deng W, Zamarin D, Lankes H, Kim H, Chino J, Banberry B, Sherry N, Ghamande S, Ferguson C, Mell L, Hollman L, Matthews C, O'Malley D, Olawaiye A, Hopp E, O’Cearbhaill R, Aghajanian C, Schilder R. EP075/#462 Radiation quality and workflow in NRG GY017: anti PD-L1 (atezolizumab) as an immune primer or concurrently with RT for node positive locally advanced cervical cancer. International Journal of Gynecologic Cancer 2023;33:A107. |
Non-Peer Reviewed Educational Products |
1. Hopp E, Bradley WH. Salpingo-oophorectomy. The SCORE Portal. http://www.surgicalcore.org. Published July 2016. |
2. Hopp E, Bradley WH. Hysterectomy. The SCORE Portal. http://www.surgicalcore.org. Published June 2016. |